文献速递脊柱关节炎

生物制剂改善病情抗风湿药在低与高关节计数的银屑病关节炎患者中同样有效

Biologic disease-modifying anti-rheumatic drugs are equally effective in psoriatic arthritis patients with low and high joint counts.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

本研究比较首次使用生物制剂改善病情抗风湿药(bDMARD)在低关节计数(LJC)与高关节计数(HJC)银屑病关节炎(PsA)患者中的有效性。197例LJC与190例HJC患者基线特征存在差异,但粗分析和校正分析中bDMARD药物留存率均无显著差异(HR 1.09,95%CI 0.76-1.58,P=0.52)。联合传统合成DMARD(csDMARD)时药物留存率显著更优(HR 0.63,95%CI 0.47-0.85,P<0.002)。

要点

  • LJC与HJC患者bDMARD药物留存率无显著差异(HR 1.09,95%CI 0.76-1.58,P=0.52)。
  • 联合csDMARD时bDMARD留存率显著更优(HR 0.63,95%CI 0.47-0.85,P<0.002)。
  • 作者认为在未缓解且疾病负担显著时,不应因关节计数低而不给bDMARD。

核心结论

  • bDMARD在低关节计数和高关节计数患者中按药物留存率评价有效性相似。
  • 作者认为在未达到缓解且疾病负担显著的情况下,不应仅因关节计数低而不给患者使用bDMARD。

研究设计与样本

  • 本研究为PsA患者队列分析,按66/68关节计数将患者分为低关节计数(LJC,压痛或肿胀关节<3个)和高关节计数(HJC,两类关节均≥3个)两组。
  • 共纳入197例LJC患者和190例HJC患者,均有可用的66/68关节计数评估。
  • 采用单因素和多因素校正Cox回归模型分析药物留存率作为关节计数独立有效性变量。

主要发现

  • 197例LJC患者与190例HJC患者相比,除关节计数不同外,LJC患者附着点炎评分更低、指趾炎更少、残疾更轻、健康相关生活质量更好,但使用csDMARD的比例更低。
  • 尽管基线存在差异,LJC与HJC患者间bDMARD药物留存率在粗分析和校正分析中均无显著差异(HR 1.09,95%CI 0.76-1.58,P=0.52)。
  • bDMARD联合csDMARD治疗时药物留存率显著更优(HR 0.63,95%CI 0.47-0.85,P<0.002)。

关键数值与推荐

  • 低关节计数定义为压痛关节<3个或肿胀关节<3个;高关节计数定义为压痛和肿胀关节均≥3个。
  • bDMARD药物留存率比较:HR 1.09(95%CI 0.76-1.58),P=0.52。
  • bDMARD联合csDMARD与未联合者比较:HR 0.63(95%CI 0.47-0.85),P<0.002。

临床怎么用

  • 作者认为在未达到缓解且疾病负担显著时,不应因患者仅表现为低关节计数而不给bDMARD。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A lack of representation in pivotal trials currently limits guidance for the use of biologic DMARDs (bDMARDs) in PsA patients with a low number of actively inflamed joints. The aim of this study was to compare the effectiveness of a first bDMARD in PsA patients with a low vs high number of affected joints. METHODS: PsA patients with available 66/68 joint count assessments were divided into low joint count (LJC) patients when presenting with <3 tender or <3 swollen joints or high joint count (HJC) patients with ≥3 joints in both categories. We studied drug retention as a joint count independent effectiveness variable in LJC and HJC patients in univariate and multivariable adjusted Cox regression models. RESULTS: A total of 197 LJC patients differed not only in joint counts, but also had lower enthesitis scores, less often dactylitis, less disability and a better health-related quality of life at first bDMARD initiation than 190 HJC patients. However, LJC patients were less often on conventional synthetic DMARDs (csDMARDs). Despite these differences at baseline, bDMARD retention was not significantly different between LJC and HJC patients in both crude and adjusted analyses [hazard ratio (HR) 1.09 (95% CI 0.76, 1.58), P = 0.52]. Furthermore, bDMARD retention was significantly better [HR 0.63 (95% CI 0.47, 0.85), P < 0.002] when administered with csDMARD co-therapy. CONCLUSIONS: bDMARDs were similarly effective in terms of drug retention in patients with low and high joint counts. In the setting of absent remission and a significant disease burden, bDMARDs should not be withheld from patients because they exhibit only a low joint count.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Möller B, Scholz GA, Amsler J, et al. Biologic disease-modifying anti-rheumatic drugs are equally effective in psoriatic arthritis patients with low and high joint counts. Rheumatology (Oxford). 2024. PMID: 37676822. doi:10.1093/rheumatology/kead455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。